The Evolving Role of VEGF Targeted Agents in Treating Solid Tumors

Download these slides to review the most recent data informing optimal use of VEGFR-targeted TKIs in treating patients with solid organ tumors, then use the slides in your own presentations.
Tanios Bekaii-Saab
Tanios Bekaii-Saab, MD, FACP
Richard Finn, MD
Elizabeth R. Plimack, MD, MS
Format: Microsoft PowerPoint (.ppt)
File Size: 1.51 MB
Released: November 15, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

In this slideset from Clinical Care Options (CCO), experts provide insights on HER2 testing and targeted therapy in advanced gastrointestinal cancers

Axel Grothey Headshot Axel Grothey, MD Michael F. Press, MD, PhD Released: September 25, 2020

Downloadable slideset covering the latest data on treating patients with pancreatic cancer and BRCA mutations or other actionable alterations, from Clinical Care Options (CCO)

person default Dirk Arnold, MD, PhD Released: September 21, 2020

Downloadable slideset reviewing the latest data on molecular testing considerations for patients with pancreatic cancer, from Clinical Care Options (CCO)

Michael J. Pishvaian, MD, PhD Released: September 21, 2020

From Clinical Care Options (CCO), expert commentary by Dr Richard Finn on the use of atezolizumab plus bevacizumab for advanced HCC

Richard Finn, MD Released: September 15, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue